Gritstone bio, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $16.3M | $19.9M | $48.2M | $1.3M | $1.3M | $1.2M |
| Operating income | −$139.6M | −$120.4M | −$75.2M | −$26.7M | −$18.9M | −$65.6M |
| Net income | −$138.5M | −$119.7M | −$75.1M | −$26.2M | −$18.0M | −$64.8M |
| Total assets | $177.8M | $240.8M | $278.1M | $221.6M | $184.4M | $189.6M |
| Total liabilities | $125.9M | $70.0M | $62.0M | $54.8M | $50.0M | $40.4M |
| Equity | $51.9M | $170.8M | $216.1M | $166.7M | $134.3M | $149.1M |
| EPS (diluted) | $-1.20 | $-1.32 | $-0.95 | $-2.79 | — | — |
| Shares out. | 87.7M | 72.7M | 49.0M | 37.0M | 29.2M | 28.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −854.3%
- Net margin
- −847.3%
- Return on equity
- −267.1%
- Return on assets
- −77.9%
- Return on capital (ROCE)
- −92.8%
- Liabilities / assets
- 70.8%
- Debt / equity
- 2.43×
- Book value / share
- $0.59
- Revenue growth (YoY)
- −18.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -14.72distress
- Accruals / assets
- −9.5%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Redmile Group, LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivership · Unregistered equity sale · Modified shareholder rights · Change in control · Director / officer change · Other material eventApr 4, 2025
- Regulation FD disclosureFeb 25, 2025
- Regulation FD disclosureFeb 14, 2025
- Entered a material agreement · Bankruptcy or receivership · Completed an acquisition or disposition · Director / officer changeJan 3, 2025
- Regulation FD disclosureDec 13, 2024
- Regulation FD disclosureNov 29, 2024
- Entered a material agreement · Bankruptcy or receivership · New financial obligationNov 15, 2024
- Costs from exit or disposal · Delisting / listing-standard noticeOct 16, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.